136 related articles for article (PubMed ID: 7704494)
1. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O
Lung Cancer; 1994 Dec; 11(5-6):373-84. PubMed ID: 7704494
[TBL] [Abstract][Full Text] [Related]
2. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O
Ann Oncol; 1994 Sep; 5(7):641-3. PubMed ID: 7993841
[TBL] [Abstract][Full Text] [Related]
3. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
Fujii M; Kiura K; Okabe K; Toki H; Kimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
Stockler M; Raghavan D; McCaughan BC; Grygiel J; McNeil E; Gianoutsos P; Lee JH
Med J Aust; 1992 May; 156(10):698-700. PubMed ID: 1377770
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
10. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
Joss RA; Bürki K; Dalquen P; Schatzmann E; Leyvraz S; Cavalli F; Ludwig C; Siegenthaler P; Alberto P; Stahel R
Cancer; 1990 Jun; 65(11):2426-34. PubMed ID: 2159837
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of combination chemotherapy with mitomycin C, vindesine and cisplatin (MVP therapy) in advanced non-small cell lung cancer].
Setoguchi J; Sawada M; Onodera H; Sigeta M; Nakai M; Nakano K; Kanatsuna T; Kondoh M; Hotta T; Hayashi H
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2399-403. PubMed ID: 2546504
[TBL] [Abstract][Full Text] [Related]
13. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
[TBL] [Abstract][Full Text] [Related]
15. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
Einhorn LH; Loehrer PJ; Williams SD; Meyers S; Gabrys T; Nattan SR; Woodburn R; Drasga R; Songer J; Fisher W
J Clin Oncol; 1986 Jul; 4(7):1037-43. PubMed ID: 3088219
[TBL] [Abstract][Full Text] [Related]
16. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
Fukuoka M; Negoro S; Masuda N; Kusunoki Y; Matsui K; Ryu S; Takifuji N; Kudoh S; Takada M
Am J Clin Oncol; 1992 Feb; 15(1):18-22. PubMed ID: 1312768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
